Clinical Conversations (CE): T-Cell-Engaging Bispecific Antibodies in Cancer: What the Non-Oncology Pharmacist Needs to Know about Acute Toxicities (CE)
About this episode
This episode discusses T-cell-engaging bispecific antibodies and their associated acute toxicities in cancer treatment.
T-cell-engaging bispecific antibodies represent a major therapeutic and scientific advancement in the treatment of several types of cancer. However, they carry a risk of some unique acute toxicities, such as cytokine release syndrome and neurologic toxicity. This podcast reviews this emerging drug class and strategies for recognition and management of their unique adverse events. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.
Topics covered
- cancer treatment
- acute toxicities
- pharmacology
- bispecific antibodies
- drug management
- oncology
Keywords
- T-cell-engaging bispecific antibodies
- acute toxicities
- cytokine release syndrome
- neurologic toxicity
- cancer therapy
- pharmacist education
Mentioned in this episode
Organizations: American Society of Health-System Pharmacists©
Products: T-cell-engaging bispecific antibodies
More episodes of ASHPOfficial
- Informatics Bytes: Interdisciplinary Collaboration to Reduce Low-Value Alert Noise in the Electronic Health Record
- Clinical Conversations: SCSS: Filtering the Latest: Staying Current With Kidney Care
- Advocating for Impact: The New Practitioner Playbook: Legislative Edition
- Insights and Connections: A Real Conversation About 340B
Explore listener stats, chart rankings, contacts and more on the ASHPOfficial podcast page.